Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Arcellx, Inc.

ACLXNASDAQ
Healthcare
Biotechnology
$66.53
$0.00(0.00%)
U.S. Market is Open • 15:53

Arcellx, Inc. Fundamental Analysis

Arcellx, Inc. (ACLX) shows weak financial fundamentals with a PE ratio of -16.70, profit margin of -6.07%, and ROE of -51.13%. The company generates $0.0B in annual revenue with weak year-over-year growth of -2.16%.

Key Strengths

Cash Position12.72%
Current Ratio3.99

Areas of Concern

ROE-51.13%
Operating Margin-6.76%
We analyze ACLX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -485.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-485.1/100

We analyze ACLX's fundamental strength across five key dimensions:

Efficiency Score

Weak

ACLX struggles to generate sufficient returns from assets.

ROA > 10%
-33.22%

Valuation Score

Excellent

ACLX trades at attractive valuation levels.

PE < 25
-16.70
PEG Ratio < 2
1.12

Growth Score

Weak

ACLX faces weak or negative growth trends.

Revenue Growth > 5%
-2.16%
EPS Growth > 10%
-36.05%

Financial Health Score

Excellent

ACLX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.12
Current Ratio > 1
3.99

Profitability Score

Weak

ACLX struggles to sustain strong margins.

ROE > 15%
-5113.00%
Net Margin ≥ 15%
-6.07%
Positive Free Cash Flow
No

Key Financial Metrics

Is ACLX Expensive or Cheap?

P/E Ratio

ACLX trades at -16.70 times earnings. This suggests potential undervaluation.

-16.70

PEG Ratio

When adjusting for growth, ACLX's PEG of 1.12 indicates fair valuation.

1.12

Price to Book

The market values Arcellx, Inc. at 8.26 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

8.26

EV/EBITDA

Enterprise value stands at -17.88 times EBITDA. This is generally considered low.

-17.88

How Well Does ACLX Make Money?

Net Profit Margin

For every $100 in sales, Arcellx, Inc. keeps $-6.07 as profit after all expenses.

-6.07%

Operating Margin

Core operations generate -6.76 in profit for every $100 in revenue, before interest and taxes.

-6.76%

ROE

Management delivers $-51.13 in profit for every $100 of shareholder equity.

-51.13%

ROA

Arcellx, Inc. generates $-33.22 in profit for every $100 in assets, demonstrating efficient asset deployment.

-33.22%

Following the Money - Real Cash Generation

Operating Cash Flow

Arcellx, Inc. generates limited operating cash flow of $-202.44M, signaling weaker underlying cash strength.

$-202.44M

Free Cash Flow

Arcellx, Inc. generates weak or negative free cash flow of $-205.57M, restricting financial flexibility.

$-205.57M

FCF Per Share

Each share generates $-3.56 in free cash annually.

$-3.56

FCF Yield

ACLX converts -5.40% of its market value into free cash.

-5.40%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-16.70

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

1.12

vs 25 benchmark

P/B Ratio

Price to book value ratio

8.26

vs 25 benchmark

P/S Ratio

Price to sales ratio

103.58

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.12

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.99

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.51

vs 25 benchmark

ROA

Return on assets percentage

-0.33

vs 25 benchmark

ROCE

Return on capital employed

-0.45

vs 25 benchmark

How ACLX Stacks Against Its Sector Peers

MetricACLX ValueSector AveragePerformance
P/E Ratio-16.7029.43 Better (Cheaper)
ROE-51.13%800.00% Weak
Net Margin-607.01%-20145.00% (disorted) Weak
Debt/Equity0.120.30 Strong (Low Leverage)
Current Ratio3.994.64 Strong Liquidity
ROA-33.22%-17936.00% (disorted) Weak

ACLX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Arcellx, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-287.84%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-188.71%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ